ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+4.57%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.71B
AUM Growth
+$5.71B
(-11%)
Cap. Flow
-$801M
Cap. Flow
% of AUM
-14.03%
Top 10 Holdings %
Top 10 Hldgs %
73.58%
Holding
34
New
1
Increased
10
Reduced
17
Closed
4
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$187M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$65.1M |
| 3 |
uniQure
QURE
|
$20.2M |
| 4 |
Vera Therapeutics
VERA
|
$14.1M |
| 5 |
Alkermes
ALKS
|
$12.9M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$445M |
| 2 |
Sarepta Therapeutics
SRPT
|
$171M |
| 3 |
United Therapeutics
UTHR
|
$87.6M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$82.5M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$44.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $860M | 15.05% | 4,980,000 -238,000 | -5% | -$41.1M |
|
|
2
United Therapeutics
UTHR
$13.8B
| $681M | 11.93% | 2,370,000 -305,000 | -11% | -$87.6M |
|
3
argenx
ARGX
$43.6B
| $648M | 11.34% | 1,175,000 -60,177 | -5% | -$33.2M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $567M | 9.94% | 1,875,000 -147,222 | -7% | -$44.6M |
|
5
Krystal Biotech
KRYS
$4.27B
| $366M | 6.4% | 2,660,000 -71,000 | -3% | -$9.76M |
|
6
Kymera Therapeutics
KYMR
$2.95B
| $286M | 5.01% | 6,555,555 +95,555 | +1% | +$4.17M |
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $212M | 3.71% | 12,222,222 | – | – |
|
8
Avidity Biosciences
RNA
$5.99B
| $200M | 3.51% | 7,050,000 -575,000 | -8% | -$16.3M |
|
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $196M | 3.43% | 4,150,000 +1,379,900 | +50% | +$65.1M |
|
|
10
Akero Therapeutics
AKRO
$3.74B
| $187M | 3.27% | +3,500,000 | New | +$187M |
|
11
Soleno Therapeutics
SLNO
$3.6B
| $172M | 3.01% | 2,050,000 -475,000 | -19% | -$39.8M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $169M | 2.96% | 5,400,000 -341,666 | -6% | -$10.7M |
|
13
Arrowhead Research
ARWR
$3.05B
| $167M | 2.93% | 10,600,000 -511,111 | -5% | -$8.08M |
|
14
Merus
MRUS
$4.98B
| $166M | 2.91% | 3,155,555 +155,555 | +5% | +$8.18M |
|
|
15
Vera Therapeutics
VERA
$1.38B
| $148M | 2.6% | 6,300,000 +598,100 | +10% | +$14.1M |
|
16
Amicus Therapeutics
FOLD
$2.34B
| $103M | 1.81% | 18,000,000 -2,500,000 | -12% | -$14.3M |
|
|
17
Alkermes
ALKS
$4.78B
| $83M | 1.45% | 2,900,000 +450,000 | +18% | +$12.9M |
|
18
Ocular Therapeutix
OCUL
$2.12B
| $68.7M | 1.2% | 7,400,000 -660,000 | -8% | -$6.12M |
|
19
89bio
ETNB
$1.34B
| $66.3M | 1.16% | 6,750,000 +400,000 | +6% | +$3.93M |
|
|
CNTA
20
Centessa Pharmaceuticals
CNTA
$2.25B
| $65.7M | 1.15% | 5,000,000 +950,000 | +23% | +$12.5M |
|
|
21
uniQure
QURE
$896M
| $50.5M | 0.88% | 3,625,000 +1,450,000 | +67% | +$20.2M |
|
22
Taysha Gene Therapies
TSHA
$797M
| $50.1M | 0.88% | 21,700,000 +1,700,001 | +9% | +$3.93M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $48.1M | 0.84% | 375,000 -3,475,000 | -90% | -$445M |
|
24
Tourmaline Bio
TRML
$601M
| $40.9M | 0.72% | 2,555,555 +130,555 | +5% | +$2.09M |
|
25
BioCryst Pharmaceuticals
BCRX
$1.74B
| $40.3M | 0.71% | 4,500,000 -4,200,000 | -48% | -$37.6M |
|